Cohort Profile: The National Institute for Health Research Health Informatics Collaborative: Hepatitis B Virus (NIHR HIC HBV) research dataset
Wang T. et al, (2023), International Journal of Epidemiology, 52, e27 - e37
An immune dysfunction score for stratification of patients with acute infection based on whole-blood gene expression
Cano-Gamez E. et al, (2022), Science Translational Medicine, 14
Impact of the COVID-19 pandemic on routine surveillance for adults with chronic hepatitis B virus (HBV) infection in the UK.
Campbell C. et al, (2022), Wellcome open research, 7
Hepatitis B virus (HBV) viral load, liver and renal function in adults treated with tenofovir disoproxil fumarate (TDF) vs. untreated: a retrospective longitudinal UK cohort study
Wang T. et al, (2021), BMC Infectious Diseases, 21
Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure
Smith DA. et al, (2021), Nature Communications, 12
Variable short duration treatment versus standard treatment, with and without adjunctive ribavirin, for chronic hepatitis C: the STOP-HCV-1 non-inferiority, factorial RCT
Cooke GS. et al, (2021), Efficacy and Mechanism Evaluation, 8, 1 - 90
Longitudinal Analysis of the Utility of Liver Biochemistry as Prognostic Markers in Hospitalized Patients With Corona Virus Disease 2019.
Wang T. et al, (2021), Hepatology communications, 5, 1586 - 1604
Longitudinal Analysis of the Utility of Liver Biochemistry as Prognostic Markers in Hospitalized Patients With Corona Virus Disease 2019
Wang T. et al, (2021), Hepatology Communications, 5, 1586 - 1604
Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy
Smith DA. et al, (2021), Journal of Viral Hepatitis
National Institute for Health Research Health Informatics Collaborative: development of a pipeline to collate electronic clinical data for viral hepatitis research.
Smith DA. et al, (2020), BMJ health & care informatics, 27
Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia
Nguyen D. et al, (2020), Journal of Hepatology, 73, 794 - 799